Sensible Biotechnologies Raises $47 Million for Cell-Made mRNA

Sensible Biotechnologies has secured $47 million in financing to scale its platform for naturally modified mRNA made in living cells, according to Thepharmaletter. The UK-based company is developing mRNA made in living cells and reported financing intended to support the scaling of that platform.

Financing includes Series A and non-dilutive funding

The $47 million financing comprises a Series A led by Oxford Science Enterprises and up to $20 million in non-dilutive funding, Thepharmaletter reported. The non-dilutive component comes from the government of Slovakia and the European Union.

Thepharmaletter identified Oxford Science Enterprises as the lead for the Series A. The reported financing structure combines the Series A with the stated non-dilutive support from Slovakia and the European Union.

Focus remains on mRNA made in living cells

Sensible Biotechnologies is focused on naturally modified mRNA made in living cells, according to Thepharmaletter. The publication reported that the company plans to use the financing to scale its cell-made mRNA platform.

For pharmaceutical and biotech sales professionals following mRNA technology activity, the event centers on financing for a platform designed around mRNA production in living cells. The available report identifies the company’s UK base, its cell-made mRNA focus, the Series A lead, and the government and European Union sources of the non-dilutive funding.

Reported transaction details

• Sensible Biotechnologies secured $47 million in financing.
• The company is UK-based.
• Its platform is focused on naturally modified mRNA made in living cells.
• Oxford Science Enterprises led the Series A.
• Up to $20 million is non-dilutive funding from the government of Slovakia and the European Union.

All financing, company, and platform details in this brief were reported by Thepharmaletter.